Can Telemedicine Optimize the HCV Care Cascade in People Who Use Drugs? Features of an Innovative Decentralization Model and Comparison with Other Micro-Elimination Strategies.
HCV
PWUD
people who use drugs
telemedicine
Journal
Biology
ISSN: 2079-7737
Titre abrégé: Biology (Basel)
Pays: Switzerland
ID NLM: 101587988
Informations de publication
Date de publication:
24 May 2022
24 May 2022
Historique:
received:
23
04
2022
revised:
21
05
2022
accepted:
21
05
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
People who use drugs (PWUDs) are a crucial population in the global fight against viral hepatitis. The difficulties in linkage to care, the low adherence to therapy, the frequent loss to follow-up and the high risk of re-infection make the eradication process of the hepatitis C virus (HCV) really hard in this viral reservoir. Several management and treatment models have been tested with the aim of optimizing the HCV care cascade in PWUDs. Models of decentralization of the care process and integration of services seem to provide the highest success rates. Giving this, telemedicine could favor the decentralization of diagnostic-therapeutic management, key for the implementation of linkage to care, reduction of waiting times, optimization of adherence and results and reduction of the costs. The purpose of this literature review is to examine the role and possible impact of telemedicine in optimizing the HCV care cascade, comparing the different care models that have shown to improve the linkage to care and therapeutic adherence in this special population.
Identifiants
pubmed: 35741326
pii: biology11060805
doi: 10.3390/biology11060805
pmc: PMC9219847
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Gilead Sciences (Italy)
ID : not able to provide grant number at the moment
Références
Lancet Gastroenterol Hepatol. 2022 May;7(5):396-415
pubmed: 35180382
Life (Basel). 2020 Dec 30;11(1):
pubmed: 33396802
Rev Esp Enferm Dig. 2019 Jul;111(7):550-555
pubmed: 31215210
Hepatology. 2013 Oct;58(4):1215-24
pubmed: 23504650
Intern Med J. 2021 Aug;51(8):1344-1347
pubmed: 34423535
J Infect Dis. 2013 Jan 15;207(2):281-7
pubmed: 23129759
PLoS One. 2020 Mar 10;15(3):e0229239
pubmed: 32155165
Int J Drug Policy. 2021 Aug;94:103235
pubmed: 33838399
J Hepatol. 2016 Dec;65(6):1094-1103
pubmed: 27520879
J Public Health Manag Pract. 2019 Sep/Oct;25 Suppl 5, Tribal Epidemiology Centers: Advancing Public Health:S97-S100
pubmed: 31348196
Int J Drug Policy. 2019 Jul;69:1-7
pubmed: 31003171
Lancet Infect Dis. 2016 Dec;16(12):1409-1422
pubmed: 27615026
Liver Int. 2021 Aug;41(8):1979-1980
pubmed: 34153175
J Antimicrob Chemother. 2019 Nov 1;74(Suppl 5):v17-v23
pubmed: 31782500
Int J Drug Policy. 2021 Feb;88:103031
pubmed: 33221615
Sex Transm Dis. 2016 Oct;43(10):648-55
pubmed: 27631361
Diagnostics (Basel). 2021 Dec 11;11(12):
pubmed: 34943573
Clin Infect Dis. 2020 Apr 15;70(9):1900-1906
pubmed: 31233117
Hepatology. 2020 Feb;71(2):686-721
pubmed: 31816111
Gastroenterology. 2004 Nov;127(5 Suppl 1):S35-50
pubmed: 15508101
J Viral Hepat. 2019 Jan;26(1):101-108
pubmed: 30315691
J Hepatol. 2019 May;70(5):839-846
pubmed: 30654067
Rev Esp Enferm Dig. 2021 Jun;113(6):432-435
pubmed: 33267593
EClinicalMedicine. 2021 Oct 17;41:101148
pubmed: 34712928
Int J Drug Policy. 2017 Sep;47:34-46
pubmed: 28797498
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161
pubmed: 29310928
N Engl J Med. 2015 Dec 31;373(27):2608-17
pubmed: 26575258
Biology (Basel). 2022 Apr 16;11(4):
pubmed: 35453808
PLoS One. 2019 Jun 3;14(6):e0217471
pubmed: 31158245
J Correct Health Care. 2018 Apr;24(2):127-136
pubmed: 29566611
J Hepatol. 2020 Nov;73(5):1170-1218
pubmed: 32956768
Addict Disord Their Treat. 2017 Jun;16(2 Suppl 1):S1-S23
pubmed: 28701904
Ann Intern Med. 2019 May 7;170(9):594-603
pubmed: 30959528
Int J Drug Policy. 2022 Mar;101:103570
pubmed: 34954493
Am J Gastroenterol. 2021 Jun 1;116(6):1248-1255
pubmed: 34074828
Telemed J E Health. 2019 Sep;25(9):791-801
pubmed: 30325701
Int J Drug Policy. 2019 Oct;72:146-159
pubmed: 31147142
Clin Gastroenterol Hepatol. 2021 Jun;19(6):1139-1150.e30
pubmed: 32896632
J Viral Hepat. 2021 Jan;28(1):209-212
pubmed: 32854135
Lancet Gastroenterol Hepatol. 2020 Sep;5(9):809-818
pubmed: 32526210
J Viral Hepat. 2020 Dec;27(12):1437-1443
pubmed: 32810330
J Virus Erad. 2018 Apr 1;4(2):118-122
pubmed: 29682305
Int J Environ Res Public Health. 2021 Apr 01;18(7):
pubmed: 33916226
Telemed J E Health. 2021 May;27(5):488-494
pubmed: 32882154
Aliment Pharmacol Ther. 2022 Mar;55(5):568-579
pubmed: 34877667
Lancet Glob Health. 2021 Apr;9(4):e431-e445
pubmed: 33639097
PLoS One. 2017 May 19;12(5):e0177341
pubmed: 28542351
Clin Infect Dis. 2019 Jul 2;69(2):323-331
pubmed: 30329042
Hepatology. 2016 Apr;63(4):1090-101
pubmed: 26390137
Int J Drug Policy. 2022 Apr;102:103588
pubmed: 35101667
Drug Alcohol Depend. 2021 Mar 1;220:108525
pubmed: 33461152
Liver Int. 2021 Apr;41(4):649-655
pubmed: 33486885
Clin Gastroenterol Hepatol. 2015 Nov;13(11):2005-14.e1-3
pubmed: 25724704
Viruses. 2020 Jul 10;12(7):
pubmed: 32664198
Open Forum Infect Dis. 2019 Apr 09;6(4):ofz166
pubmed: 31049365
World J Gastroenterol. 2008 Mar 21;14(11):1657-63
pubmed: 18350596
Liver Int. 2019 Dec;39(12):2244-2260
pubmed: 31125496
United European Gastroenterol J. 2021 Dec;9(10):1109-1118
pubmed: 34697911
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207
pubmed: 29074409
J Telemed Telecare. 2017 Jan;23(1):83-87
pubmed: 26748393
Pathogens. 2020 May 31;9(6):
pubmed: 32486342
Hepatol Med Policy. 2018 Jun 5;3:7
pubmed: 30288330
Front Public Health. 2017 Dec 18;5:348
pubmed: 29326922
J Viral Hepat. 2014 Mar;21(3):198-207
pubmed: 24438681
Addiction. 2018 May;113(5):868-882
pubmed: 29359361
Ann Hepatol. 2017 Oct 16;16(6):874-880
pubmed: 29055923
J Hepatol. 2021 Jan;74(1):31-36
pubmed: 32777322